Meanwhile in the real world, the news got some coverage today:
"Of the estimated 537 million people worldwide who have diabetes, 19% to 34% will develop a diabetic foot ulcer (DFU) in their lifetime. Approximately 20% of people who develop a DFU will require lower-extremity amputation, either minor (below the ankle), major (above the ankle), or both."
"The analysis of the first 16 patients (n=8 per group) found that the median percentage reduction in wound surface area in the active CYP-006TK group after 10 weeks’ follow-up was 87.6%, compared to 51.1% in the control group."
As said above, after another 5 patients enrolled, if similar results repeated across the full 30 patient trial, statistical confidence likely to be around the somewhat arbitrary 95% confidence level that investors look at as success in trials, for CYP-006TK vs the SOC control group.
And for the lucky patients in the CYP-006TK group perhaps a future amputation of a limb avoided for 3 or 4 patients, for all the crap from the very poorly informed detractors above, from some simple maths.
CYP Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)